Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial

Göran Tornling, Rohit Batta, View ORCID ProfileJoanna Porter, Thomas Bengtsson, Kartikeya Parmar, Reema Kashiva, Anders Hallberg, Anne Katrine Cohrt, Kate Westergaard, Carl-Johan Dalsgaard, Johan Raud
doi: https://doi.org/10.1101/2021.01.26.21250511
Göran Tornling
1Respiratory Medicine Division, Department of Medicine Solna, Karolinska Institutet, SE-171 77 Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rohit Batta
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Porter
3UCL Respiratory, University College London & Department of Thoracic Medicine, University College Hospitals London, London NW1 2PG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joanna Porter
Thomas Bengtsson
4StatMind AB, Scheelevägen 17, SE-223 70 LUND, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kartikeya Parmar
5Department of Medicine, Nodal officer at 1200-bed COVID-19 hospital, Civil Hospital and B J Medical College, Asarwa, Ahmedabad GUJARAT, India 380016
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reema Kashiva
6Department of Medicine, Noble Hospitals Pvt. Ltd, 153 Magarpatta City Road, Hadapsar, Pune MAHARASHTRA, India 411013
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Hallberg
7Department of Medicinal Chemistry, Uppsala University, SE-751 23 Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Katrine Cohrt
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Westergaard
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl-Johan Dalsgaard
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: carl-johan.dalsgaard@vicorepharma.com
Johan Raud
2Vicore Pharma AB, Kronhusgatan 11, SE-411 05 Gothenburg, Sweden
8Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Although several therapies have been evaluated for treatment of COVID-19, the morbidity and mortality in COVID-19 are still significant, and the need for safe and effective drugs remains high even after launch of vaccine programs.

Methods We conducted a double-blind, randomized, placebo-controlled trial with the novel oral angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients with C-reactive protein 50-150 mg/L but not needing mechanical ventilation. Patients were randomly assigned to oral C21 (100 mg twice daily) or placebo for 7 days in addition to standard of care, including glucocorticoids and remdesivir.

Results 106 patients underwent randomization (51 in the C21 group and 55 in the placebo group). At day 14 after start of treatment, the proportion of patients still requiring supplemental oxygen was significantly reduced by 90% in the C21 group compared to the placebo group (p=0.003). Moreover, fewer patients required mechanical ventilation (one C21 patient and four placebo patients), and C21 was associated with a numerical reduction in the mortality rate (one and three deaths in the C21 and placebo group, respectively). Treatment with C21 was safe and well tolerated.

Conclusions As studied in hospitalized COVID-19 patients, C21 on top of standard of care led to a clinically beneficial improvement in respiratory function compared to placebo, paving the way for a pivotal randomised controlled trial.

This study is registered at ClinicalTrials.gov with identifier NCT04452435.

Competing Interest Statement

G. Tornling reports personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; and holding of shares in Vicore Pharma. R. Batta reports grants from LifeArc Medical Research Charity, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; In addition, R. Batta has a patent UK2004209.9 pending, a patent UK2009574.1 pending, and a patent US17/113,416 pending. J. Porter, has nothing to disclose. T. Bengtsson reports personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work. K. Parmar and R. Kashiva report grants from Vicore Pharma, during the conduct of the study. A. Hallberg reports personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work. A.K. Cohrt and K. Westergaard report personal fees from Vicore Pharma, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work. C.-J. Dalsgaard reports grants from LifeArc Medical Research Charity, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; In addition, J. Dalsgaard has a patent UK2004209.9 pending, a patent UK2009574.1 pending, and a patent US17/113,416 pending. J. Raud reports grants from LifeArc Medical Research Charity, during the conduct of the study; personal fees from Vicore Pharma, outside the submitted work; In addition, J. Raud has a patent UK2004209.9 pending, a patent UK2009574.1 pending, and a patent US17/113,416 pending.

Clinical Trial

NCT04452435

Funding Statement

The trial was funded by Vicore Pharma and the independent medical research charity LifeArc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committees and registrations numbers: Noble Hospital Institutional Ethics Committee, Noble Hospitals Pvt. Ltd., Room No 5, Clinical Research Department Noble Annex, 153 A, Magarpatta City Road, Hadapsar Hadapsar, 411013 India, ECR/259/Inst/MH/2013/RR-19. Ethics Committee Metas Adventist Hospital Metas Adventist Hospital, 13-B, Nondh No 0363 To 0365, RS No21, Opp, Chowpati, Main Road, Athwalines CITY, Surat Gujarat, 395001 India, ECR/1323/Inst/GJ/2019. Sir Gangaram Hospital Ethics Committee Sir Ganga Ram Hospital, Ethics Committee, Sir Ganga Ram Hospital Old, Rajinder Nagar, New-Delhi, 110060 India, ECR/20/Inst/DL/2013/RR-2019. Institutional Ethics Committee, GMC, Nagpur Government Medical College and Hospital, Nagpur, Government Medical College, Medical Square, Hanuman Nagar, Nagpur Maharashtra, 440003 India, ECR/43/Inst/MH/2013/RR-19. Institutional Ethics Committee S.L., Raheja Hospital S.L. Raheja Hospital (A Fortis Associate) Raheja Rugnalaya Marg, Mahim (W), Mumbai MAHARASHTRA 400016 India, ECR/70/Inst/MH/2013/RR-19. The Institutional Ethics Committee, B.J. Medical College & Civil Hospital, B.J. Medical College & Civil Hospital, Office of Medical Superintendent Civil Hospital Ahmedabad, Ahmedabad Gujarat, 380016 India, ECR/72/Inst/GJ/2013/RR-19. Poona Medical Research Foundation Ruby Hall Clinic, 40, Sassoon road, Pune, Pune Maharashtra, 411001 India, ECR/24/Inst/MH/2013/RR-19. Unity Hospital Ethics Committee, Unity Trauma Center and Icu, N-4 Janki Park Society Aai Mata Road, Paravat Patiya, Surat Gujarat, 395010 India, ECR/1226/Inst/GJ/2019. Siddhi Hospital Laproscopy And IEC, Siddhi Hospital Laproscopy, Dhankawade-Patil Township, Pune Satara Road, Balaji Nagar, Dhankawadi Pune, Pune Maharashtra, 411043 India,ECR/1228/Inst/MH/2019. Rhythm Heart Institute Ethics Committee, Rhythm Heart Institute, Near Siddharth Bunglows Sama- Savli Road, VADODARA, Vadodara Gujarat, 390022 India, ECR/224/Inst/GJ/2013/RR-19.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be made available to researchers who provide a scientifically sound proposal. Proposals should be directed to carl-johan.dalsgaard@vicorepharma.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 28, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
Göran Tornling, Rohit Batta, Joanna Porter, Thomas Bengtsson, Kartikeya Parmar, Reema Kashiva, Anders Hallberg, Anne Katrine Cohrt, Kate Westergaard, Carl-Johan Dalsgaard, Johan Raud
medRxiv 2021.01.26.21250511; doi: https://doi.org/10.1101/2021.01.26.21250511
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
Göran Tornling, Rohit Batta, Joanna Porter, Thomas Bengtsson, Kartikeya Parmar, Reema Kashiva, Anders Hallberg, Anne Katrine Cohrt, Kate Westergaard, Carl-Johan Dalsgaard, Johan Raud
medRxiv 2021.01.26.21250511; doi: https://doi.org/10.1101/2021.01.26.21250511

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (453)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (158)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5270)
  • Forensic Medicine (3)
  • Gastroenterology (196)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (700)
  • Health Policy (360)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (164)
  • Infectious Diseases (except HIV/AIDS) (5889)
  • Intensive Care and Critical Care Medicine (363)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (767)
  • Nursing (43)
  • Nutrition (131)
  • Obstetrics and Gynecology (143)
  • Occupational and Environmental Health (234)
  • Oncology (480)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (98)
  • Psychiatry and Clinical Psychology (864)
  • Public and Global Health (2023)
  • Radiology and Imaging (349)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)